<SEC-DOCUMENT>0001193125-19-125090.txt : 20190429
<SEC-HEADER>0001193125-19-125090.hdr.sgml : 20190429
<ACCEPTANCE-DATETIME>20190429155855
ACCESSION NUMBER:		0001193125-19-125090
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190429
DATE AS OF CHANGE:		20190429
EFFECTIVENESS DATE:		20190429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		19775794

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d704037ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule <FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:21pt; font-family:Times New Roman" ALIGN="center"><B>BIOGEN INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g704037g38h07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Biogen Announces Three New Nominees for Election to Board of Directors </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Nominees Bring Decades of Management and Global Operating Experience, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Including at Leading Healthcare Companies </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cambridge, Mass. &#150; April</B><B></B><B>&nbsp;29, 2019</B> &#150; Biogen (Nasdaq: BIIB) today announced the nomination of John R. Chiminski, William A.
Hawkins and Jesus B. Mantas to stand for election to the company&#146;s board of directors at its 2019 annual meeting of stockholders, scheduled for June&nbsp;19, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Chiminski is Chair of the board and Chief Executive Officer of Catalent, Inc., a global provider of advanced delivery technologies and development
solutions for drugs, biologics and consumer health products. Mr.&nbsp;Hawkins is a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm, and is the former Chairman and Chief Executive Officer of Medtronic, Inc., a global
leader in medical technology. Mr.&nbsp;Mantas is the Managing Partner and General Manager leading worldwide strategy, offerings, digital platforms, innovation and thought leadership for IBM Global Business Services, the $17&nbsp;billion unit of IBM
that helps global enterprises with their digital transformations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We have heard the calls from our shareholders and have acted by nominating John,
Bill and Jesus to join the Biogen Board at this important time for our company,&#148; said Stelios Papadopoulos, Ph.D., Biogen&#146;s Chairman. &#147;We are confident that each of them will provide valuable insights and expertise as we continue our
work discovering and developing innovative treatments for patients around the world all the while dedicated to maximizing value on behalf of our shareholders over the long term.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am excited by the nomination of John, Bill and Jesus and the additional fresh perspectives that they will bring to our Board. I look forward to
working with them to optimize the allocation of Biogen&#146;s cash flows for the benefit of all shareholders,&#148; stated Alexander J. Denner, Ph.D., Chair of the Corporate Governance Committee. Dr.&nbsp;Denner continued, &#147;Today&#146;s
announcement is a significant step in the board&#146;s refreshment, and we will continue the process with a view toward further diversifying and enhancing the makeup of the board.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to announce the nomination of John, Bill and Jesus for election to Biogen&#146;s Board. Their diverse backgrounds and experience in
scientific, medical, and digital innovation are highly complementary to our pioneering vision,&#148; said Michel Vounatsos, Biogen&#146;s Chief Executive Officer. &#147;We believe they will add to the wealth of our existing expertise while also
bringing new perspectives to our Board as we continue to work to maximize value for our shareholders and advance our leadership in bringing breakthrough therapies to patients.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">| More | </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Chiminski, Mr.&nbsp;Hawkins and Mr.&nbsp;Mantas are being nominated at the 2019 annual meeting of
stockholders along with the existing 11 directors, who will stand for <FONT STYLE="white-space:nowrap">re-election.</FONT> If all nominees are elected, the board would expand to 14 directors, 13 of whom would be independent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About John R. Chiminski </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Chiminski has served as
the Chief Executive Officer of Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, since March 2009, as a director since February 2009 and as Chair of the
board since October 2016. Prior to that, Mr.&nbsp;Chiminski spent more than 20 years at GE Healthcare in engineering, operations and various senior leadership roles. From 2007 to 2009 Mr.&nbsp;Chiminski was President and Chief Executive Officer of
GE Medical Diagnostics, a global business with sales of $1.9&nbsp;billion. From 2005 to 2007 he served as Vice President and General Manager of GE Healthcare&#146;s Global Magnetic Resonance Business and from 2001 to 2005 as Vice President and
General Manager of Global Healthcare Services. Earlier at GE, he held a series of cross-functional leadership positions in both manufacturing and engineering, including a GE Medical Systems assignment in France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Chiminski received a B.S. from Michigan State University and an M.S. from Purdue University, both in electrical engineering, as well as an M.S. in
management from the Kellogg School of Management at Northwestern University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About William A. Hawkins </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Hawkins serves as a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm. Mr.&nbsp;Hawkins is the former Chairman and Chief
Executive Officer of Medtronic, Inc., a global leader in medical technology. He was at Medtronic from 2002 until 2011. After retiring from Medtronic, he served as President and Chief Executive Officer of Immucor, a private equity backed global
leader in transfusion and transplant medicine from October 2011 to July 2015. From 1998 to 2001 Mr.&nbsp;Hawkins served as President and Chief Executive Officer of Novoste Corporation, an interventional cardiology company. Prior to that,
Mr.&nbsp;Hawkins served in a variety of senior roles at American Home Products, a consumer, pharma and medical device company, Johnson&nbsp;&amp; Johnson, a healthcare company, Guidant Corporation, a medical products company, and Eli Lilly and
Company, a global pharmaceutical company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Hawkins also serves as a Director of Avanos Medical, Inc., a medical technology company, as Chairman
of Bioventus, LLC and Chairman of 4 Tech and as a Director of Trice Medical, Inc., AsKBio; Virtue Labs, Cerius, Keratin Biosciences and Baebies, Inc., all of which are medical products companies. Mr.&nbsp;Hawkins is Vice Chair of the Duke University
Board of Trustees and is Chair of the Duke University Health System. Mr.&nbsp;Hawkins was elected as a member of the AIMBE College of Fellows and the National Academy of </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Engineering. He has a dual degree in electrical and biomedical engineering from Duke University and an M.B.A. from the University of Virginia&#146;s Darden School of Business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Jesus B. Mantas </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mantas is the Managing
Partner and General Manager leading worldwide strategy, offerings, digital platforms, innovation and thought leadership for IBM Global Business Services, the $17&nbsp;billion unit of IBM that helps global leading enterprises design, transform and
operate their businesses with digital and cloud technologies. He also serves on the board of IBM Services, the world largest technology services provider, and <FONT STYLE="white-space:nowrap">co-chairs</FONT> the IBM Hispanic diversity council.
Prior to his current role, he led globally multiple units in IBM, including Cognitive Process Transformation, Business Consulting and Global Process Services. From 2010 to 2014 Mr.&nbsp;Mantas lived in Brazil and led IBM Global Business Services in
Latin America. From 2006 through 2010 he was Vice President of IBM Enterprise Sector in North America. Prior to joining IBM, Mr.&nbsp;Mantas was a partner in the High Technology practice of PricewaterhouseCoopers Consulting and an officer in the Air
Force of Spain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mantas serves in the World Economic Forum Global Artificial Intelligence Council and has been recognized as Top 25 Global
Consulting Leader, Top 100 Hispanic IT Executive and Great Minds in STEM. He has degrees in telecommunications, software engineering and business administration from the Polytechnic University of Madrid and has served as professor at the Paul Merage
School of Business, University of California Irvine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Biogen</B> At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen
discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world&#146;s first global biotechnology companies,
Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and
only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer&#146;s disease and dementia, movement disorders, neuromuscular disorders, acute neurology,
neurocognitive disorders, pain, and ophthalmology. Biogen also commercializes biosimilars of advanced biologics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We routinely post information that may
be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media &#150; Twitter, LinkedIn, Facebook, YouTube. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biogen, its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection
with the matters to be considered at Biogen&#146;s 2019 annual meeting of stockholders. Biogen intends to file a proxy statement with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) in connection with such solicitation of proxies
from stockholders. STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT WHEN IT BECOMES AVAILABLE AS IT WILL CONTAIN IMPORTANT INFORMATION. Information regarding ownership of Biogen stock and other securities by Biogen directors and
executive officers is included in their SEC filings on Forms 3, 4 and 5, which can be found through the Biogen website (www.biogen.com) in the section &#147;Investors&#148; or through the SEC&#146;s website at www.sec.gov. Additional information
about Biogen&#146;s directors and executive officers and their interests is set forth in Biogen&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018, which was filed with the SEC
on February&nbsp;6, 2019, and Biogen&#146;s proxy statement for its 2018 annual meeting of stockholders, which was filed with the SEC on April&nbsp;27, 2018, and in Biogen&#146;s other SEC filings, which can be found through Biogen&#146;s website
(www.biogen.com) in the section &#147;Investors&#148; or through the SEC&#146;s website at www.sec.gov. More detailed and updated information regarding the identity of potential participants, and their direct or indirect interests, by security
holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with Biogen&#146;s 2019 annual meeting of stockholders. Stockholders will be able to obtain any proxy statement, any
amendments or supplements to the proxy statement and other documents filed by Biogen with the SEC for no charge at the SEC&#146;s website at www.sec.gov. Copies will also be available at no charge at Biogen&#146;s website at www.biogen.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biogen Safe Harbor </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains
forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to: our business activities; our strategy and plans; the potential of our commercial
business and pipeline programs; capital allocation and investment strategy; the potential election of Mr.&nbsp;Chiminski, Mr.&nbsp;Hawkins and Mr.&nbsp;Mantas to the Biogen Board of Directors; the potential expansion of the Biogen Board of Directors
at the 2019 annual meeting of stockholders; and the expected benefits from the potential election to the Biogen Board of Directors of Mr.&nbsp;Chiminski, Mr.&nbsp;Hawkins and Mr.&nbsp;Mantas. These forward-looking statements may be accompanied by
words such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;except,&#148; &#147;forecast,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148;
&#147;possible,&#148; &#147;will,&#148; &#147;would&#148; and other words and terms of similar meaning. You should not place undue reliance on these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including,
without limitation: our dependence on sales from our products; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; failure to protect and enforce our data, intellectual property and other
proprietary rights and uncertainties relating to intellectual </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property claims and challenges; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; failure to compete
effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our growth and strategic initiatives; the risk that positive results in a clinical trial may
not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; the occurrence of adverse
safety events; delay in approval of our drug candidates; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any
forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the SEC. These statements are based on our
current beliefs and expectations and speak only as of the date of this news release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDIA CONTACT:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Caouette</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+ 617 679 4945</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">public.affairs@biogen.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INVESTOR CONTACT:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matt Calistri</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 781 464 2442</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">IR@biogen.com</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g704037g38h07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g704037g38h07.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M8:,<-&G"%*K4G:G+DFZBFYM<\IJ+U<=(<J3/8/\ AWGX(Q_R/_B@''_0/TO
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M^>/>"@!I_P _A36GE8:T\K!B@88H 4<#TQ^&*1(M !0 4 % !0 4 % !0 4
;% !0 4 % !0 4 % !0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
